Osteoarthritis (OA) is a degenerative joint disease and a major cause of pain and disability in older adults. We have previously identified epidermal growth factor receptor (EGFR) signaling as an important regulator of cartilage matrix degradation during epiphyseal cartilage development. To study its function in OA progression, we performed surgical destabilization of the medial meniscus (DMM) to induce OA in two mouse models with reduced EGFR activity, one with genetic modification (Egfr Wa5/1 mice) and the other one with pharmacological inhibition (gefitinib treatment). Histological analyses and scoring at 3 months post-surgery revealed increased cartilage destruction and accelerated OA progression in both mouse models. TUNEL staining demonstrated that EGFR signaling protects chondrocytes from OA-induced apoptosis, which was further confirmed in primary chondrocyte culture. Immunohistochemistry showed increased aggrecan degradation in these mouse models, which coincides with elevated amounts of ADAMTS5 and matrix metalloproteinase 13 (MMP13), the principle proteinases responsible for aggrecan degradation, in the articular cartilage after DMM surgery. Furthermore, hypoxia-inducible factor 2a (HIF2a), a critical catabolic transcription factor stimulating MMP13 expression during OA, was also upregulated in mice with reduced EGFR signaling. Taken together, our findings demonstrate a primarily protective role of EGFR during OA progression by regulating chondrocyte survival and cartilage degradation.
INTRODUCTION
Osteoarthritis (OA) is a progressive and degenerative disorder of the joint primarily characterized by the destruction of articular cartilage. Articular cartilage is predominantly composed of collagen, proteoglycans and other matrix proteins. Loss of large proteoglycan, aggrecan, decreases cartilage compressive stiffness and precedes the damage to the collagen fibrillar network, which is responsible for tensile properties of the tissue. The structural and functional integrity of articular cartilage relies on the balance between anabolic and catabolic activities of chondrocytes. The pathology of OA in cartilage involves the production of pro-inflammatory cytokines, inflammation, degradation of extracellular matrix (ECM) by proteases, chondrocyte hypertrophy and apoptosis. 1 Moreover, the subchondral bone is inevitably altered with cortical plate thickening, enhanced bone remodeling and osteophyte formation. 2 The past decade has witnessed significant advances in deciphering the basic mechanism by which OA develops using genetically modified and surgical animal models, but there are as yet no disease modifying treatments available. It remains imperative to understand what drives cartilage degeneration during OA. Growth factors, such as transforming growth factor beta (TGF-b), insulin-like growth factors, bone morphogenic proteins and fibroblast growth factors, regulate synthesis and maintenance of cartilage ECM and therefore, play important roles in cartilage homeostasis and OA development. We recently demonstrated that epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, and one of its cognate ligands, TGF-a, are important for cartilage matrix degradation during endochondral ossification. [3] [4] Deficiency of EGFR activity either globally or specifically in chondrocytes causes expansion of the hypertrophic zone in the growth plate 3, 5 and delayed formation of secondary ossification center in long bones at early postnatal stage. 6 Consistently, TGF-a null mice exhibited similar developmental phenotypes. 4 Mechanistic studies revealed that activation of EGFR signaling stimulates the expression of matrix metalloproteinases (MMPs), including MMP9, 13 and 14, and receptor activator of nuclear factor-kB ligand (RANKL) in hypertrophic chondrocytes via b-catenin-dependent and -independent pathways, resulting in increased cartilage matrix degradation by chondrocytes and osteoclasts at the chondroosseous junctions. 6 EGFR ligands are membrane-bound proteins requiring ectodomain shedding to release the functional peptides. The major sheddase for TGF-a is TNFa-converting enzyme, also known as a disintegrin and metalloprotease 17 (ADAM17). 7 Studies of cartilage-specific TNF-a-converting enzyme knockout mice revealed a similar growth plate phenotype, providing further evidence that EGFR signaling stimulates the degradation of cartilage matrix. [8] [9] Since cartilage ECM degradation is a critical step toward OA pathogenesis, we hypothesized that EGFR and its ligands constitute another growth factor signaling pathway regulating OA development. Indeed, previous reports implied that this pathway might play a catabolic role in OA pathology. It was reported that the amount of TGF-a is elevated by articular chondrocytes in experimentally induced OA and human OA. [10] [11] Disruption of mitogen-inducible gene 6 (mig-6), a negative feedback inhibitor of EGFR activity, resulted in a degenerative joint OA-like disease in mice. [12] [13] [14] Moreover, mice deficient in MMP13 activity either globally 15 or conditionally in chondrocytes 16 were protected from OA development induced by surgery. In the present study, in order to directly investigate the role of EGFR in OA development, we performed destabilization of the medial meniscus (DMM) to induce OA in mouse models with reduced EGFR activity. This OA surgery is well characterized and it induces progressive cartilage degeneration with little synovial inflammation. 17 Surprisingly, we found that these mice show more severe cartilage destruction compared to control mice. Furthermore, histological analyses revealed that loss of EGFR activity accelerates chondrocyte apoptosis and increases cartilage matrix degradation, which coincide with the upregulation of proteinases (ADAMTS5 and MMP13), and a catabolic transcription factor, HIF2a. These results uncover an important function of EGFR in protecting articular cartilage during OA progress and suggest this protein as a potential target for OA treatment. , n59, an EGFR inhibitor; LC Laboratories, Woburn, MA, USA) treatment via oral gavage immediately after surgery, once every other day, for 12 weeks. In both models, there was no significant difference in body weight between control and EGFR deficient group at the beginning of surgery and at 3 months after surgery when the knee joints were harvested.
MATERIALS AND METHODS
Experimental OA was induced by DMM surgery and performed by a single surgeon (XZ) in these two mouse models as described previously. 17 Only male mice were used in our study because male 129 mice develop more severe OA than females. 19 Briefly, under general anesthesia, the right knee joint capsule was exposed and the medial meniscotibial ligament was transected under microscope to give destabilization of the medial meniscus. A sham operation was performed on the left knee joint in which the ligament was visualized but not transected. Mice were maintained in their preoperative groups, allowed unrestricted cage exercise, and were weighed weekly until they were euthanized 12 weeks after surgery. All animal works performed in this study were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania.
Histological analysis of OA cartilage After euthanasia, bilateral knee joints were harvested free of soft tissues, fixed in 4% paraformaldehyde overnight, decalcified in 0.5 mol?L 21 ethylene diamine tetraacetic acid (EDTA) (pH 7.4) for 4 weeks at 4 6 C and embedded in paraffin. Serial 5-mm-thick sagittal sections were cut across the medial compartment of the joint. Two sections within every consecutive six sections were stained with Safranin O/Fast green and hematoxylin and the one with better morphology was used for quantification. Each knee yielded about 15 sections for scoring by two blinded observers (XZ and ME-I) using modified Mankin's methods. 20 In brief, each section was assigned a score, which is the sum of cartilage structure (0-5), chondrocytes (0-3), Safranin-O staining (0-5) and tidemark (0-1). Each knee received a EGFR and osteoarthritis XR Zhang et al 2 score from the section with the maximal score. The results of Mankin score represent the mean of maximal scores in each group. To characterize the loss of articular cartilage, cartilage area (total) and Safranin O-stained area (uncalcified) were outlined and quantified on projected images of about 15 sections per bone selected as above followed by averaging. Thickness of each area was determined by averaging five thicknesses evenly distributed across the entire cartilage. To quantify changes in hypertrophic chondrocytes in the shamoperated knees, the number of hypertrophic chondrocytes in tibial articular cartilage was counted based on their morphology (enlarged chondrocyte lacunae with a lack of Safranin-O stain around a collapsed cells) and divided by articular cartilage area.
Immunohistochemistry and TUNEL staining Serial sections adjacent to those with representative Safranin O-stained images were dewaxed in xylene and rehydrated through a graded series of alcohols for immunohistochemical evaluation. Briefly, after antigen retrieval with boiling in sodium citrate buffer, endogenous peroxidase activity was quenched in 3% H 2 O 2 for 15 min and washed in phosphate buffered saline (PBS). Sections were then blocked in serum for 30 min followed by incubation with the primary antibody in humidified chamber at 4 6 C overnight. Biotinylated secondary antibody was added for 30 min on the second day, followed by an avidin-biotinylated horseradish peroxidase complex according to the manufacturer's directions (Vectastain ABC Kit; Vector Laboratories, Burlingame, CA, USA). Finally, peroxidase activity was revealed by immersion in DAB substrate (Dako, Glostrup, Denmark). The following primary antibodies were used: rabbit anti-aggrecanase generatedaggrecan neoepitope NITEGE, rabbit anti-MMP-generated aggrecan-neoepitope DIPEN (gifts from Dr John S Mort), rabbit anti-MMP13 (ab75606; Abcam, Cambridge, MA, USA), rabbit anti-ADAMTS5 (ab41037; Abcam), rabbit anti-HIF2a (NB100-122; Novus Biologicals, Littleton, CO, USA). TUNEL staining was carried out on paraffin sections using ApopTag Plus Peroxidase in Situ Apoptosis Detection Kit (S7101; Millipore, Billerica, MA, USA) according to the manufacturer's instructions.
Primary chondrocytes, qRT-PCR and apoptosis assay Primary epiphyseal chondrocytes were obtained from rat newborn pups as described previously. 3 We recently reported that primary chondrocytes derived from Egfr wa5/1 mice shows a slightly decrease in extracellular signal-regulated kinases (ERK) phosphorylation after being treated with epidermal growth factor (EGF) compared to WT cells, suggesting that the EGFR activity in chondrocytes from Egfr wa5/1 mice is modestly suppressed. 6 In the second model, we compared OA development in WT mice treated with either vehicle or gefitinib, an EGFR kinase inhibitor. 22 Previously, we have demonstrated that similar inhibitor treatment results significant bone loss at both trabecular and cortical sites in young mice. 23 EGFR and osteoarthritis XR Zhang et al 3 DMM surgery was performed in the right knees of 3-month-old skeletally mature mice in both models to induce OA. The left knees received sham operation. Three months after surgery, knee joints were harvested for histological analyses. The sham-operated knees appeared normal in morphology and their Mankin scores representing the severity of OA were negligible (less than 1) in all groups (data not shown). In DMM-operated knees, while WT mice exhibited typical OA features, Egfr Wa5/1 mice had marked increases in cartilage surface fibrillation, clefting and erosion down to the tidemark (Figure 1a) . Moreover, total cartilage area and thickness, particularly to WT (n510) mice after DMM surgery. * P,0.05; ** P,0.01; *** P,0.001.
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the uncalcified area and thickness, at both medial femoral condyle and medial tibial plateau were reduced in Egfr Wa5/1 mice in comparison with WT mice (Figure 1b) .
Further scoring by Mankin's method revealed significant 19% and 36% increases of OA scores at medial femoral condyle and medial tibial plateau, respectively, in Egfr Wa5/1 mice compared to those in WT mice (Figure 1c) .
In gefitinib-treated mice, OA damages on the articular cartilage was relatively milder than those in Egfr Wa5/1 mice, but still more severe than their vehicle-treated controls with increased fibrillation, clefting and erosion at the surface of articular cartilage (Figure 2a ). While we did not observe overall loss of total articular cartilage in gefitinib-treated mice, the area and thickness of uncalcified cartilage were remarkably decreased in those mice compared to their vehicle controls (Figure 2b) . Mankin scores revealed a significant 28% increase at medial femoral condyle and a trend of 22% increase at medial tibial plateau in these mice compared to controls (Figure 2c Figure 3b ) compared to their respective controls. We found that it was difficult to perform similar measurement at the DMM knees because of severe erosion and/or loss of articular cartilage in the EGFR deficient group. These findings indicate that EGFR prevents chondrocyte hypertrophy and may explain why mice with reduced EGFR signaling are predisposed to the development of osteoarthritis.
Reduced EGFR activity promotes apoptosis in cartilage chondrocytes after DMM surgery Hypertrophic chondrocytes undergo cell death and are replaced by bone in the process of endochondral ossification. However, this process at the articular surface could lead to osteoarthritis. Chondrocyte apoptosis has been observed during OA progression and the apoptotic rate is positively correlated with the severity of cartilage damage. [24] [25] Indeed, the contribution of apoptosis to OA was further demonstrated by using caspase inhibitors, which block cell death and decrease severity of cartilage lesions in posttraumatic OA. 26 EGFR has multifaceted actions on cells from a variety of tissues and is capable of regulating their proliferation, differentiation, survival, migration, and adhesion. To investigate the role of EGFR in chondrocyte apoptosis during OA development, TUNEL staining was performed on knee joints at 3 months post-surgery in mouse models with reduced EGFR activity. In DMM-operated knees from control mice, only 8%-12% of chondrocytes in articular cartilage underwent apoptosis and most of these apoptotic chondrocytes were located in the calcified zone (Figure 4a and 4b) . In contrast, 30% and 24% of chondrocytes in DMM-operated knees from Egfr wa5/1 mice and gefitinib-treated mice, respectively, were TUNEL-positive and many of them extended into the middle and deep zones (Figure 4a and 4b) , suggesting that EGFR protects chondrocytes from OA-induced cell death.
To confirm this finding in vitro, we isolated epiphyseal chondrocytes from neonatal pups and used serum starvation together with TNF-a, a pro-inflammatory cytokine and a well-known inducer of chondrocyte apoptosis in OA, 27 to induce cell death in these cells. Ethidium bromide/acridine orange staining showed that removal of serum alone increased the percentage of apoptotic cells from 2% to 14% and that addition of TNF-a further elevated it to 21% (Figure 4c ). However, cotreatment with TGF-a completely abrogated the apoptotic signals of serum depletion and TNF-a, reducing the percentage of apoptotic cells to the level similar to those grown in normal serum-containing medium (Figure 4c ). Taken together, these in vivo and in vitro results clearly indicate that EGFR transduces survival signals to chondrocytes during OA progression.
Aggrecan degradation is accelerated in OA knee joints from mice with reduced EGFR activity Proteolytic cleavage of aggrecan weakens the cartilage matrix and is a key event in OA pathogenesis. [28] [29] Next, we examined aggrecan degradation products in articular cartilage after DMM surgery by immunohistochemistry. 
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Staining of aggrecan-neoepitopes NITEGE (aggrecanasegenerated aggrecan cleavage fragment) and DIPEN (MMP-generated aggrecan cleavage fragment) showed that aggrecan degradation products generated by either aggrecanases or MMPs were significantly enhanced in both femoral and tibial articular cartilage areas in . Arrow points to a late apoptotic cell. ss, serum starvation. ** P,0.01; *** P,0.001.
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( Figure 1a and 2a) , indicating that activation of EGFR signaling pathway suppresses cartilage matrix degradation during OA development. ADAMTS5 is the major aggrecanase in mouse cartilage and deletion of this proteinase blocks cartilage degradation and prevents OA progression. [30] [31] Immunostaining revealed that ADAMTS5 amounts were markedly increased in articular cartilage after DMM surgery in both mouse models with reduced EGFR activity, compared to those in their respective control mice (Figure 6a and 6b, right panels). Similar observations were also obtained in sham-operated knees (Figure 6a and 6b, left panels), implying that EGFR signaling regulates adamts5 expression in chondrocytes. Indeed, qRT-PCR experiment with primary chondrocytes further demonstrated that activation of EGFR in chondrocytes inhibits the mRNA expression of adamts5 (Figure 6c ). MMP13 is another critical proteinase responsible for cartilage degradation during OA development. [15] [16] 32 Our previous work found that activation of EGFR signaling induces Mmp13 expression in chondrocytes, while inhibition of EGFR signal by gefitinib attenuates its expression in the growth plate. 3 Immunostaining of MMP13 was weak and mostly located below the tidemark in sham-operated knees. In line with the above growth plate results, we found that MMP13 amount was further reduced in articular cartilage from Egfr Wa5/1 mice and gefitinib-treated mice (Figure 6a and 6b, left panels). In contrast, MMP13 immunostaining occurred in the uncalcified cartilage above the tide marker in DMM knee joints of Egfr Wa5/1 mice and gefitinib-treated mice and its amounts in those mice were significantly elevated compared to their respective control mice (Figure 6a and 6b, right panels). Taken together, our results indicate that inhibition of EGFR signaling promotes aggrecan degradation during OA development by increasing the amounts of important catabolic enzymes, such as ADAMTS5 and MMP13.
To understand the mechanism for the opposite regulation of Mmp13 expression by EGFR in sham-and DMMoperated knee joints, we next analyzed the expression of hif2a, a transcription factor highly expressed in OA development and essential for Mmp13 expression in chondrocytes, [33] [34] [35] in the articular cartilage of those mouse models after DMM surgery. Immunostaining revealed a considerably increased number of HIF2a-positive cells in articular cartilage from Egfr Wa5/1 and gefitinib-treated mice at 12 weeks after surgery, compared to their respective control mice (Figure 7a and 7b) . To confirm these in vivo results, we evaluated the regulation of HIF2a expression by EGFR signaling in primary epiphyseal chondrocytes culture. qRT-PCR demonstrated that TGF-a significantly decreased hif2a expression in primary chondrocytes (Figure 7c ). Hence, our results suggest that one mechanism for EGFR to suppress Mmp13 expression is likely through inhibiting hif2a expression during OA progression. In normal knees, since the basal level of HIF2a is very low in the cartilage, 34 EGFR signaling must use alternative transcription factor(s) to activate the expression of Mmp13.
DISCUSSION
The present study identifies a novel role of EGFR signaling in articular cartilage homeostasis and OA progression. We demonstrated that a genetically modified mouse model (Egfr Wa5/1 ) and a pharmacological mouse model (gefitinib treatment), both of which have reduced EGFR activity, exhibit accelerated articular cartilage destruction in knee joints after surgical induction of OA. This observation is correlated with increased chondrocyte apoptosis and aggrecan degradation. Further mechanistic studies suggest that this is likely due to augmented expression of 
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catabolic proteinases (ADAMTS5 and MMP13) and a transcription factor (HIF2a) targeting cartilage matrix degradation after suppressing EGFR activity. Our findings initially appeared surprising to us because they are not consistent with our previous conclusion that chondrogenic EGFR signaling stimulates cartilage ECM degradation by upregulating MMPs and stimulating osteoclastogenesis at the chondro-osseous junction at postnatal developmental stage. 3 the severe OA phenotypes observed in mig-6 knockout mice is likely due to highly elevated EGFR activity. Note that our Egfr Wa5/1 mouse model has modest decrease in chondrogenic EGFR activity compared to WT mice while a chondrogenic EGFR knockout mouse model (col2-cre Egfr Wa5/flox ) we established previously has more drastic decrease in EGFR activity. 6 We are currently studying the OA progression in this mouse model. Excessive proteolysis has long been recognized as a major contributory factor to cartilage matrix degradation in OA. A variety of proteases have been implicated, ranging from lysosomal cysteine proteases to MMP family members. Among them, ADAMTS5 and MMP13 are the most critical ones in mediating cartilage ECM degradation because their expression is greatly enhanced in osteoarthritic knees [38] [39] [40] [41] and because mice deficient in either ADAMTS5 or MMP13 have diminished OA progression after DMM surgery. [15] [16] 30, 42 Interestingly, while ADAMTS5 amounts were similarly increased in both sham and DMM knee joints from mice with reduced EGFR activity, MMP13 amounts were decreased in sham knees, which is consistent with our previous report that EGFR signaling stimulates MMP13 expression in chondrocytes, but were increased in DMM knee joints from mice with reduced EGFR activity compared to their controls. The apparent contradiction could be explained by enhanced hif2a expression in DMM knee joints after suppression of EGFR activity. Previous reports [33] [34] [35] have shown that HIF2a is a major regulator for Mmp13 but not adamts5 genes in chondrocytes. Elevated HIF2a amount thus surpasses the other pathway(s) which mediates the stimulatory effect of EGFR signaling on Mmp13 expression.
In conclusion, in the present study, we provide the first direct evidence for the involvement of EGFR signaling in the OA development. Modestly decreased EGFR activity in our two mouse models accelerates articular cartilage destruction, which is associated with increased chondrocyte apoptosis and cartilage matrix degradation by ADAMTS5 and MMP13. This study lays the groundwork for understanding the role of EGFR and its cognate ligands in the maintenance of articular cartilage and in the pathogenesis of OA. Further studies to maximize its anabolic actions while minimizing its catabolic actions in cartilage will shed light on targeting this novel pathway in OA treatment.
